Development and Optimization of Hemostatic Peptides for Hemorrhage Control on Battlefields – Hemostatic Peptides
- Authors
- Corporate Authors
- Defence R&D Canada - Toronto, Toronto ONT (CAN);McGill Univ, Montreal Que (CAN) Lady Davis Institute of Medical Research, Jewish General Hospital
- Abstract
- The goal of the research contract conducted for the Defence Research and Development Canada – Toronto, was to develop a hemostatic biocompatible surface to treat hemorrhagic injuries sustained on the battlefield. During the first year of the contract, a candidate hemostatic amphipathic helical peptide (an ideal amphipathic helical peptide or IAP) was developed (published in Biochemical Journal 412: 545-51 2008) and different biocompatible surfaces were tested (published in Journal of Biomaterials Research, Part B: Applied Biomaterials, 2008 Sep 5). Once the peptide and biomaterial were identified, the second year was dedicated to testing IAP coupled to different surfaces and we finally settled on IAP coupled to polyethylene glycol and poly(allylamine) (PEG-PAA) for further testing. In vivo work testing this material was carried out on small animals (rabbits) and subsequently on large animals (pigs) during the second and third year. We have data that demonstrates the feasibility of such material to arrest bleeding in vivo by reducing hemorrhage by 40-50%.
- Keywords
- Peptides;Hemorrhage control
- Report Number
- DRDC-TORONTO-CR-2009-014 — Contractor Report
- Date of publication
- 28 Feb 2009
- Number of Pages
- 37
- DSTKIM No
- CA032389
- CANDIS No
- 531554
- Format(s):
- Electronic Document(PDF)
Document 1 of 1
- Date modified: